A once-weekly injection schedule is expected to carry through to potential phase 3 and commercial formulations
"With telogen effluvium, you will not lose all your hair, you will not go bald, and it will grow back, so it's not a permanent situation," Dr
Large clinical trials have established that semaglutide reduces systemic inflammation, decreases systolic blood pressure, and lowers the risk of major adverse cardiovascular events like heart attacks and strokes
#biotech #pharma #drugdevelopment #FDA To view or add a comment, sign in - : : The global GLP-1 Agonists Market, valued at US$53.74 billion in 2024, stood at US$64.42 billion in 2025 and is projected to advance at a resilient CAGR of 13.0% from 2025 to 2033, culminating in a forecasted valuation of US$170.75 billion by the end of the period
And when you have friends like Amanda Sarich and Robert Blair, its pretty easy to trust their picks are going to be unique, tasty, and probably something I havent seen before